grant
The Genetic Epidemiology of Radiation-Associated Contralateral Breast Cancer
Organization SLOAN-KETTERING INST CAN RESEARCHLocation NEW YORK, UNITED STATESPosted 6 May 2025Deadline 30 Apr 2030
NIHUS FederalResearch GrantFY2025AI basedAcuteBRCA 1/2BRCA1/2Bayesian learningBayesian machine learningBenefits and RisksBreast CancerBreast Cancer PatientBreast Cancer Risk FactorBreast Cancer survivorBreast Tumor PatientCDS1CHEK2CHEK2 geneCHK2Cancer Causing AgentsCancer ControlCancer Control ScienceCancer Susceptibility GeneCancer-Predisposing GeneCancersCarcinogensCaringCase-Base StudiesCase-Comparison StudiesCase-Compeer StudiesCase-Referent StudiesCase-Referrent StudiesCase/Control StudiesCausalityCds1 kinaseCell BodyCellsChk2 protein kinaseClassificationClinicCohort StudiesConcurrent StudiesContra-lateral BreastContralateral BreastDNA DamageDNA InjuryDNA seqDNA sequencingDNAseqDataEnvironment-Related Malignant NeoplasmEnvironmental CancerEnvironmental Malignant NeoplasmEpidemiologyEquilibriumEthnic GroupEthnic PeopleEthnic PopulationEthnic individualEthnicity PeopleEthnicity PopulationEtiologyExposure toFutureGene variantGenesGeneticGenetic DeterminismGenetic ModelsGenetic PredispositionGenetic Predisposition to DiseaseGenetic SusceptibilityGenetic propensityGerm LinesGerm-Line MutationGoalsHereditaryHereditary MutationIndividualInheritedInherited PredispositionInherited SusceptibilityInterviewIonizing Electromagnetic RadiationIonizing radiationKnowledgeLibrariesLife StyleLifestyleMachine LearningMalignant Breast NeoplasmMalignant NeoplasmsMalignant TumorMissense MutationModelingOncogensOutcomePP1425ParticipantPathogenicityPatientsPerformancePredispositionProviderQuestionnairesRAD53RadiationRadiation GeneticsRadiation SensitivityRadiation ToleranceRadiation therapyRadiation-Ionizing TotalRadiosensitivityRadiotherapeuticsRadiotherapyResearchRiskRisk EstimateRisk FactorsRisk-associated variantRoleSecond CancerSecond Primary CancersSecondary MalignancySecondary Malignant NeoplasmSiteSusceptibilitySystematicsTherapeuticVariantVariationWomanallelic variantartificial intelligence basedbalancebalance functionbase editingbrca genebreast cancer diagnosisbreast cancer riskcare resourcescase-controlled studiescausationcheck point kinase 2checkpoint kinase 2clinical decision-makingclinical riskcohortcomputer based predictioncustomized therapycustomized treatmentdesigndesigningdisease causationenvironment related cancerenvironmental radiationepidemiologicepidemiologicalethnic subgroupethnicity groupexome sequencingexome-seqfitnessgene-radiation therapygenetic determinantgenetic epidemiologic studygenetic epidemiologygenetic etiologygenetic mechanism of diseasegenetic predictorsgenetic variantgenetic vulnerabilitygenetically predisposedgenomic variantgerm-line defectgermline varianthealth care resourcesindividualized medicineindividualized patient treatmentindividualized therapeutic strategyindividualized therapyindividualized treatmentindividuals with breast cancerionizing outputmachine based learningmalignancymalignant breast tumormissense single nucleotide polymorphismmissense single nucleotide variantmissense variantmodel buildingmulti-ethnicmultiethnicneoplasm/cancernon-geneticnongeneticnoveloncogenic agentpatient specific therapiespatient specific treatmentpatients with breast cancerperson with breast cancerpopulation basedpredictive modelingradiation absorbed doseradiation riskradiation treatmentradio-sensitivityradiosensitiveresponserisk allelerisk generisk genotyperisk locirisk locusrisk prediction algorithmrisk prediction modelrisk variantscreeningscreeningssecondary cancerserine-threonine-protein kinase Chk2social rolestudy populationtailored medical treatmenttailored therapytailored treatmenttreatment planningtreatment with radiationtumor DNAtumor cell DNAtumor-specific DNAunique treatment
Description preview
ABSTRACT
The risk of contralateral breast cancer (CBC) after a first breast cancer diagnosis is well-documented and
substantial. Radiation therapy (RT) is an important component of treatment for over half of all women with primary
breast cancer yet it is a potent carcinogen and an established risk factor for future CBC. Despite major advances
in…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click